Rajan, Arun Heery, Christopher Thomas, Anish Mammen, Andrew Perry, Susan O’Sullivan Coyne, Geraldine Guha, Udayan Berman, Arlene Szabo, Eva Madan, Ravi Ballester, Leomar Pittaluga, Stefania Donahue, Renee Tsai, Yo-Ting Lepone, Lauren Chin, Kevin Ginty, Fiona Sood, Anup Hewitt, Stephen Schlom, Jeffrey Hassan, Raffit Gulley, James Additional file 1: of Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma Table S1. Flow-cytometry analysis of immune subsets. Subsets analyzed included 9 standard immune subsets (PD-L1 and PD-1 expression analysis was performed for all standard subsets) and 96 subsets relating to maturation and function of immune cells. Table S2. Details of autoimmune adverse events associated with treatment. Table S3. Association of avelumab-related response and irAEs with prior treatment with sunitinib. Table S4. Association between steroid use and response in patients responding to treatment. (DOCX 96 kb) Thymoma;Immunotherapy;Avelumab;Immune-related adverse events;Immunosuppressive therapy;Anti-PD-L1 2019-10-22
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Efficacy_and_tolerability_of_anti-programmed_death-ligand_1_PD-L1_antibody_Avelumab_treatment_in_advanced_thymoma/10022162
10.6084/m9.figshare.10022162.v1